Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
Vir Biotechnology’s stockholders of record as of
Whether or not stockholders plan to virtually attend the Annual Meeting,
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Heather Rowe ArmstrongVP, Investor Relations email@example.com +1-415-915-4228 Media Cara MillerVP, Corporate Communications firstname.lastname@example.org +1-415-941-6746
Source: Vir Biotechnology, Inc.